# Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

> **NCT01892137** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 137 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Ingenol mebutate gel 0.05%

## Key facts

- **NCT ID:** NCT01892137
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-05
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01892137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01892137, "Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01892137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*